Amylin Pharmaceuticals, Lilly and Alkermes announced results from a 30-week study comparing the efficacy of exenatide once weekly (a long-acting release formulation of exenatide) to Byetta (the injectable version of exenatide), in type 2 diabetes. Patients treated with exenatide once weekly, an investigational therapy, showed statistically significant improvements in A1c and fasting plasma glucose from baseline compared with Byetta. Patients in both treatment groups also reported significant wei...